June 09, 2022
42
6
Click the title above for a link to open the Pharmaceutical Executive June 2022 issue in an interactive PDF format.
June 09, 2022
Features
42
6
The windfall from COVID-19 vaccines and treatments has shaken up Pharm Exec’s latest listing of the top global biopharma sales producers in record-breaking fashion, but a likely leveling off—along with challenging patent and global climates—should shift some of the spotlight to anticipated non-COVID risers and perhaps more definitive maneuvering ahead.
June 09, 2022
Features
42
6
Outlining the implications of this c-suite trend for pharma.
June 09, 2022
Features
42
6
Outlining the most important sustainability-related hurdles facing leading biopharma companies today—and current efforts underway to meet new expectations in advancing this strategic mandate.
June 09, 2022
Features
42
6
A flurry of new titles entering the executive ranks has its pros and cons.
June 09, 2022
Executive Profile
42
6
Tremeau CEO Bradford Sippy strikes a new chord with revival of old blockbuster drug—modifying it as a unique treatment for orphan hemophilia condition.
June 09, 2022
Finance
42
6
Some observations point to hope for an upturn.
June 09, 2022
Marketing
42
6
How addressing equity gaps can be a boost for brands.
June 09, 2022
Leadership
42
6
Tips for surviving a shift in executive roles.
June 09, 2022
Europe Report
42
6
Group’s ideas to change EU pricing rules draw captive audience.
June 09, 2022
From the Editor
42
6
Pharma workforce shifting amidst rise of technology in healthcare.
May 16, 2022
Washington Report
42
6
Plan to keep new methods adopted during COVID in place.
April 26, 2022
Features
42
6
As regulatory reform continues to evolve in the US and Europe, the role of regulatory affairs is poised to help shape the more personalized treatment landscape on the horizon.